1. Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 2017;24:1073274817729245.

2. Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711-42.

3. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 2018;155:1828-37.e2.

4. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. Alpha-fetoprotein, des-γ carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.

5. Ghanaati H, Alavian SM, Jafarian A, Ebrahimi Daryani N, Nassiri-Toosi M. Imaging and imaging-guided interventions in the diagnosis and management of hepatocellular carcinoma (HCC)-review of evidence. Iran J Radiol 2012;9:167-77.

6. Haug AR. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma Imaging of primary liver tumors with positron-emission tomography. Q J Nucl Med Mol Imaging 2017;61:292-300.

7. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.

8. Navin PJ, Venkatesh SK. Hepatocellular carcinoma: state of the art imaging and recent advances. J Clin Transl Hepatol 2019;7:72-85.

9. Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007;244:898-906.

10. Wu B, Zhang Y, Tan H, Shi H. Value of 18F-FDG PET/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2019; doi: 10.1007/s00261-019-01997-2.

11. Park MS, Kim S, Patel J, Hajdu CH, Do RK, et al. Hepatocellular carcinoma: detection with diffusion weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology 2012;56:140-8.

12. Ishizawa T, Masuda K, Urano Y, Kawaguchi Y, Satou S, et al. Mechanistic background and clinical applications of indocyanine green fluorescence imaging of hepatocellular carcinoma. Ann Surg Oncol 2014;21:440-8.

13. Hester CA, Rich NE, Singal AG, Yopp AC. Comparative analysis of nonalcoholic steatohepatitis versus viral hepatitis and alcohol-related liver disease-related hepatocellular carcinoma. J Natl Compr Canc Netw 2019;17:322-9.

14. Li D, Mallory T, Satomura S. AFP L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001;313:15-9.

15. Liebman HA, Furie BC, Tong M, Blanchard RA, Lo KJ, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.

16. Wang B, Zhu J, Ma X, Wang H, Qiu S, et al. Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma. Clin Chim Acta 2019;495:191-7.

17. Ono M, Ohta H, Ohhira M, Sekiya C, Namiki M. Measurements of immunoreative prothrombin, des-γ-carboxy prothrombin and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma. Am J Gastroenterol 1990;85:1149-54.

18. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, et al. Plasma des-gamma-carboxyprothrombin in the early stages of hepatocellular carcinoma. Hepatology 1990;11:481-8.

19. Pote N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol 2015;62:848-54.

20. Lim TS, Kim DY, Han KH, Kim HS, Shin SH, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol 2016;51:344-53.

21. Han C, Gao L, Bai H, Dou X. Identification of a role for serum aldoketo reductase family 1-member B10 in early detection of hepatocellular carcinoma. Oncology Letters 2018;16:7123-30.

22. DiStefano JK, Davis B. Diagnostic and prognostic potential of AKR1B10 in human hepatocellular carcinoma. Cancers (Basel) 2019;11:E486.

23. Conigliaro A, Costa V, Lo Dico A, Saieva L, Buccheri S, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer 2015;14:155.

24. Wang H, Hou L, Li A, Duan Y, Gao H, et al. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int 2014;2014:864894.

25. Qu Z, Wu J, Wu J, Ji A, Qiang G, et al. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 2017;8:80666-78.

26. Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 2015;112:532-8.

27. Liu W, Hu J, Zhou K, Chen F, Wang Z, et al. Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma. OncoTargets Ther 2017;10:3843-51.

28. Arbelaiz A, Azkargorta M, Krawczyk M, Santos-Laso A, Lapitz A, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2017;66:1125-43.

29. Wang W, Li H, Zhou Y, Jie S. Peripheral blood microvesicles are potential biomarkers for hepatocellular carcinoma. Cancer Biomark 2013;13:351-7.

30. Świtlik WZ, Bielecka-Kowalska A, Karbownik MS, Kordek R, Jabłkowski M, et al. Forms of diagnostic material as sources of miRNA biomarkers in hepatocellular carcinoma: a preliminary study. Biomark Med 2019; doi: 10.2217/bmm-2018-0485.

31. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007;132:330-42.

32. Liu Y, Pan S, Liu L, Zhai X, Liu J, et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population,. PLoS One 2012;7:e35145.

33. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther 2010;12:607-16.

34. Yang L, Zhang X, Li H, Liu J. The long noncoding RNA HOTAIR activates autophagy by upregulating ATG3 and ATG7 in hepatocellular carcinoma. Mol Biosyst 2016;12:2605-12.

35. Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 2012;29:1810-6.

36. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, et al. MicroRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011;30:4750-6.

37. Tu ZQ, Li RJ, Mei JZ, Li XH. Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular carcinoma. Int J Clin Exp Pathol 2014;7:4303-9.

38. Wang F, Ying HQ, He BS, Pan YQ, Deng QW, et al. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget 2015;6:7899-917.

39. Tsang FH, Au SL, Wei L, Fan DN, Lee JM, et al. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b. Liver Int 2015;35:1597-606.

40. Zhuang LK, Yang YT, Ma X, Han B, Wang ZS, et al. MicroRNA-92b promotes hepatocellular carcinoma progression by targeting Smad7 and is mediated by long non-coding RNA XIST. Cell Death Dis 2016;7:e2203.

41. Zhang C, Xia R, Zhang B, Wang H. The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma. BMC Cancer 2018;18:1110.

42. Ezzat WM, Amr KS, Elhosary YA, Hegazy AE, Fahim HH, et al. Detection of DNA methylated microRNAs in hepatocellular carcinoma. Gene 2019;702:153-7.

43. Xu RH, Wei W, Krawczyk M, Wang W, Luo H, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017;16:1155-61.

44. Kisiel JB, Dukek BA, Kanipakam RVSR, Ghoz HM, et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation. Hepatology 2019;69:1180-92.

45. Li Y, Zhao J, Yu S, Wang Z, He X, et al. Extracellular Vesicles Long RNA Sequencing Reveals Abundant mRNA, circRNA, and lncRNA in Human Blood as Potential Biomarkers for Cancer Diagnosis. Clin Chem 2019; doi: 10.1373/clinchem.2018.301291.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: